| E-BPO 5% uses a novel microencapsulation technology to improve therapeutic effects and reduce inflammatory lesions of rosacea. |
| E-BPO 5% is an important addition to the current therapeutic options for rosacea and demonstrates improved patient outcomes along with the potential to reduce treatment-associated irritation. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.